LRMR

3.1402.48%
FE

Frank Edward Thomas

Independent Chairman

Mr. Frank Edward Thomas serves as Director at Larimar Therapeutics, Inc. since June 2014. He serves as President at Orchard Therapeutics plc since March 18, 2020 and its Chief Operating Officer since January 2020. He was Chief Financial Officer of Orchard Therapeutics plc since January 2018 until March 2020 and served as its Chief Business Officer from January 2018 to December 2019. He has been an Independent Director at Spero Therapeutics, Inc. since July 2017 and serves as its Independent Chairman since January 10, 2025. He served as President and Chief Operating Officer of AMAG Pharmaceuticals, Inc. since April 1, 2015 until April 30, 2017 and since November 4, 2011 until April 30, 2017 respectively and served as its Executive Vice President, Chief Financial Officer and Treasurer since joining on August 1, 2011 until April 1, 2015. Mr. Thomas has experience in a leadership role at high growth life sciences companies, including significant skill and expertise at the executive level. He served as an Interim Chief Executive Officer and Interim President of AMAG Pharmaceuticals, Inc. from November 4, 2011 to May 14, 2012 and served as its Chief Financial Officer from August 1, 2011 to November 4, 2011. He served as the Chief Executive Officer and President of Chiesi USA, Inc. (alternate name Cornerstone Therapeutics Inc.) from June 2006 to March 2008. Mr. Thomas served as the Chief Operating Officer and Senior Vice President of Molecular Biometrics, Inc. from October 2008 to July 2011 and served as its Chief Financial Officer. Prior to Molecular Biometrics, Mr. Thomas spent several years at Critical Therapeutics, Inc. a public biopharmaceutical company, from April 2004 to March 2008. He served as the President of Critical Therapeutics Inc. from June 2006 to March 31, 2008 and as its Chief Executive Officer from December 21, 2006 to March 31, 2008. He served as the Chief Financial Officer of Critical Therapeutics Inc. from April 26, 2004 to August 20, 2007 and as its Treasurer from May 2004 to June 2006, Senior Vice President of Finance from December 2004 to June 2006 and Vice President of Finance from June 2004 to December 2004. He also served as Principal Accounting Officer of Critical Therapeutics until June 2006. He joined Critical Therapeutics, Inc. in April 26, 2004. He served in a variety of finance positions with Esperion Therapeutics from February 2000 to April 2004. Mr. Thomas served as Vice President of Finance and Investor Relations at Esperion Therapeutics Inc. since April 2002 and its Chief Financial Officer after serving as Esperion Therapeutics Inc.’s Senior Director of Finance and Investor Relations since January 2002. He served as Director of Finance and Controller of Esperion Therapeutics, Inc. from March 2000 to January 2002. He served as a Director of Finance and Controller at Mechanical Dynamics Inc. from September 1997 to March 2000. From July 1992 to 2000, he worked for Arthur Andersen LLP, including as an Audit Manager in the Detroit office, where he was a Certified public accountant. Mr. Thomas served as an Executive Director of Critical Therapeutics Inc. from June 2006 to March 2, 2008 and Cornerstone Therapeutics Inc. from June 2006 to March 2, 2008. He served as Director at the Massachusetts Biotechnology Council from 2007 to 2015. He had been an Independent Director of Zafgen, Inc. since June 18, 2014. Mr. Thomas holds a BBA in Business Administration from the University of Michigan in 1992.

Positions